Axiocent Product Usage: This PRODUCT IS INTENDED FOR RESEARCH USE ONLY (RUO)
Maximum results are typically observed at 4-6 months of consistent use
Research overview Other vial-size protocols Related protocols and comparisons BPC-157 + TB-500 (10 mg Blend) Dosage Protocol BPC-157 + TB-500 (20 mg Blend) Dosage Protocol TB-500 (5 mg) + BPC-157 (5 mg) Stack Dosage Protocol Tri-Heal (45 mg Blend) Dosage Protocol GLOW (70 mg Blend) Dosage Protocol KLOW (80 mg Blend) Dosage Protocol GHK-Cu (50 mg Vial) Dosage Protocol GHK-Cu (100 mg Vial) Dosage Protocol
Saueressig T, Owen PJ, Pedder H, Tagliaferri S, Kaczorowski S, Altrichter A, et al
In preclinical studies, NPI-001 has exhibited the ability to cross blood-brain and blood-retinal barriers
At the molecular level, chronic AOD9604 administration upregulates 3 adrenergic receptors in fat tissue, reversing obesityrelated suppression of these fatburning receptors [9]